JP2016033133A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016033133A5 JP2016033133A5 JP2015159977A JP2015159977A JP2016033133A5 JP 2016033133 A5 JP2016033133 A5 JP 2016033133A5 JP 2015159977 A JP2015159977 A JP 2015159977A JP 2015159977 A JP2015159977 A JP 2015159977A JP 2016033133 A5 JP2016033133 A5 JP 2016033133A5
- Authority
- JP
- Japan
- Prior art keywords
- granulated product
- preparation
- uncoated tablet
- pharmaceutically acceptable
- water
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000002360 preparation method Methods 0.000 claims 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 5
- UCHDWCPVSPXUMX-TZIWLTJVSA-N Montelukast Chemical compound CC(C)(O)C1=CC=CC=C1CC[C@H](C=1C=C(\C=C\C=2N=C3C=C(Cl)C=CC3=CC=2)C=CC=1)SCC1(CC(O)=O)CC1 UCHDWCPVSPXUMX-TZIWLTJVSA-N 0.000 claims 4
- 229960005127 montelukast Drugs 0.000 claims 4
- 150000003839 salts Chemical class 0.000 claims 4
- 239000011780 sodium chloride Substances 0.000 claims 4
- 238000005550 wet granulation Methods 0.000 claims 4
- 230000001629 suppression Effects 0.000 claims 3
- OGIDPMRJRNCKJF-UHFFFAOYSA-N TiO Inorganic materials [Ti]=O OGIDPMRJRNCKJF-UHFFFAOYSA-N 0.000 claims 2
- 239000011247 coating layer Substances 0.000 claims 2
- 229960001951 montelukast sodium Drugs 0.000 claims 2
- LBFBRXGCXUHRJY-HKHDRNBDSA-M montelukast sodium Chemical compound [Na+].CC(C)(O)C1=CC=CC=C1CC[C@H](C=1C=C(\C=C\C=2N=C3C=C(Cl)C=CC3=CC=2)C=CC=1)SCC1(CC([O-])=O)CC1 LBFBRXGCXUHRJY-HKHDRNBDSA-M 0.000 claims 2
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 claims 2
- 229910001929 titanium oxide Inorganic materials 0.000 claims 2
- 239000011248 coating agent Substances 0.000 claims 1
- 238000000576 coating method Methods 0.000 claims 1
- 238000004040 coloring Methods 0.000 claims 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 230000000087 stabilizing Effects 0.000 claims 1
- 238000003860 storage Methods 0.000 claims 1
Claims (7)
A method for stabilizing a preparation comprising montelukast or a pharmaceutically acceptable salt thereof, comprising the step of coating the preparation with a coating layer containing titanium oxide.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2015159977A JP6575031B2 (en) | 2014-07-28 | 2015-07-28 | Montelukast sodium preparation |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2014153305 | 2014-07-28 | ||
| JP2014153305 | 2014-07-28 | ||
| JP2015159977A JP6575031B2 (en) | 2014-07-28 | 2015-07-28 | Montelukast sodium preparation |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019122670A Division JP7093752B2 (en) | 2014-07-28 | 2019-07-01 | Montelukast sodium preparation |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016033133A JP2016033133A (en) | 2016-03-10 |
| JP2016033133A5 true JP2016033133A5 (en) | 2018-08-02 |
| JP6575031B2 JP6575031B2 (en) | 2019-09-18 |
Family
ID=55452210
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015159977A Active JP6575031B2 (en) | 2014-07-28 | 2015-07-28 | Montelukast sodium preparation |
| JP2019122670A Active JP7093752B2 (en) | 2014-07-28 | 2019-07-01 | Montelukast sodium preparation |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019122670A Active JP7093752B2 (en) | 2014-07-28 | 2019-07-01 | Montelukast sodium preparation |
Country Status (1)
| Country | Link |
|---|---|
| JP (2) | JP6575031B2 (en) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2017001989A (en) * | 2015-06-11 | 2017-01-05 | ニプロ株式会社 | Pharmaceutical composition and process for producing the same |
| CN108057021B (en) * | 2017-12-25 | 2019-03-19 | 南京康舟医药科技有限公司 | A kind of Montelukast sodium granules and preparation method thereof |
| TW202038918A (en) * | 2018-11-27 | 2020-11-01 | 日商協和麒麟股份有限公司 | Pharmaceutical composition |
| CN112386578B (en) * | 2020-10-26 | 2022-11-22 | 石药集团欧意药业有限公司 | Montelukast sodium chewable tablet and preparation method thereof |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20090124657A1 (en) | 2007-08-14 | 2009-05-14 | Ramesh Kappala | Pharmaceutical compositions comprising montelukast |
| WO2009153305A2 (en) | 2008-06-19 | 2009-12-23 | Sandoz Ag | Pharmaceutical compositions of montelukast sodium |
| US20110189274A1 (en) | 2008-10-06 | 2011-08-04 | Swati Mukherjee | Stable Pharmaceutical Compositions Of Montelukast Or Its Salts Or Solvates Or Hydrates |
| KR20130009553A (en) * | 2011-07-15 | 2013-01-23 | 한미약품 주식회사 | Capsule formulation comprising montelukast or a pharmaceutically acceptable salt thereof, and levocetirizine or a pharmaceutically acceptable salt thereof |
| KR101418404B1 (en) * | 2012-01-06 | 2014-07-10 | 한미약품 주식회사 | Stable pharmaceutical formulation for oral administration comprising levocetirizine or a pharmaceutically acceptable salt thereof, and montelukast or a pharmaceutically acceptable salt thereof |
| CN103239450B (en) | 2012-02-07 | 2014-11-26 | 齐鲁制药有限公司 | Rapidly-dissolving and stabile montelukast oral solid preparation and preparation method thereof |
| JP5858486B2 (en) * | 2012-05-11 | 2016-02-10 | 塩野義製薬株式会社 | Solid formulation containing ascorbic acid, sucralose and aspartame |
| CN103494785B (en) | 2013-10-09 | 2015-03-11 | 福建华海药业有限公司 | Montelukast sodium chewable tablet and preparation method thereof |
-
2015
- 2015-07-28 JP JP2015159977A patent/JP6575031B2/en active Active
-
2019
- 2019-07-01 JP JP2019122670A patent/JP7093752B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016033133A5 (en) | ||
| PH12016501236A1 (en) | Stable and palatable liquid pharmaceutical composition of phenylephrine and a maleate salt of an antihistamine | |
| NZ705578A (en) | Coated pharmaceutical composition containing regorafenib | |
| MX2016012573A (en) | Dihydropyrimidine compounds and their application in pharmaceuticals. | |
| EP3312175A4 (en) | Heteroaryl derivative or pharmaceutically acceptable salt thereof, preparation method therefor, and pharmaceutical composition for preventing or treating diseases associated with pi3 kinases, containing same as active ingredient | |
| EA201391053A1 (en) | TABLET DISPERSED IN THE MOUTH CAVITY | |
| FI3263110T3 (en) | A tablet comprising a methoxyurea derivative and mannitol particles | |
| EP3456815A4 (en) | Aqueous solution capable of being administered to living body, and method for producing same | |
| EP3453703A4 (en) | Crystalline form e of tafamidis methylglucamine salt, and preparation method and application thereof | |
| FI3248597T3 (en) | Therapeutic agent for sensorineural hearing loss | |
| JP2016532632A5 (en) | ||
| CA2922375C (en) | Alpha-tea salt forms: compositions and uses for treating disease | |
| PH12019500638A1 (en) | Composite formed into single layer, comprising candesartan and amlodipine | |
| EP3785713A4 (en) | Salt of cetagliptin, preparation method therefor, pharmaceutical composition, and use thereof | |
| WO2013017910A8 (en) | Extended release pharmaceutical compositions containing paliperidone | |
| CA3003108A1 (en) | Storage stable composition comprising rifaximin alpha | |
| EP3404033A4 (en) | C-glucoside derivative containing fused phenyl ring or pharmaceutically acceptable salt thereof, process for preparing same, and pharmaceutical composition comprising same | |
| EP3648745A4 (en) | Pharmaceutical composition including multi-unit spheroidal tablet containing esomeprazole and spheroidal pharmaceutically acceptable salt thereof, and method of preparing the pharmaceutical composition | |
| EP3530654A4 (en) | Quinolinyl-substituted carboxylic acid compound or pharmaceutically acceptable salt thereof, pharmaceutical composition thereof, and use thereof | |
| JP2011251959A5 (en) | ||
| WO2015052568A3 (en) | Solid forms of curcumin and derivatives thereof | |
| JP2016013980A5 (en) | ||
| CO2018002046A2 (en) | New oral delayed dual dexlansoprazole oral composition | |
| JP2014518280A5 (en) | ||
| EA033291B1 (en) | Dosage unit comprising ramipril and bisoprolol hemifumarate, process for the preparation thereof and method of treating hypertension |